Cipla Ltd.

Cipla has completed the transfer formalities in relation to the divestment of its entire 25% stake held in Biomab Holding, Hong Kong (Biomab) on January 22, 2016. Consequently, the company ceases to hold any stake in Biomab.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.